Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
9.73
-1.13 (-10.41%)
At close: Dec 20, 2024, 4:00 PM
9.98
+0.25 (2.57%)
After-hours: Dec 20, 2024, 6:53 PM EST
Jupiter Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
319.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 233.28K | -404.76K | -63.44% |
| Dec 31, 2021 | 638.04K | -488.20K | -43.35% |
| Dec 31, 2020 | 1.13M | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Community Health Systems | 12.55B |
| Enhabit | 1.04B |
| SIGA Technologies | 173.73M |
| Arcturus Therapeutics Holdings | 160.40M |
| National Research | 144.16M |
| Y-mAbs Therapeutics | 84.55M |
| Alpha Teknova | 36.35M |
| Taysha Gene Therapies | 9.92M |
JUNS News
- 17 days ago - Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering - GlobeNewsWire
- 19 days ago - Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq - GlobeNewsWire
- 2 years ago - Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO - Renaissance Capital